Brazil and Nigeria are emerging as key export destinations for Indian pharmaceutical companies, helping diversify India’s overseas markets amid global economic uncertainty, according to official trade data.

During the April–November period of the current financial year, pharmaceutical exports to Nigeria recorded a sharp increase, making it one of the fastest-growing destinations for Indian drug makers. Exports to Brazil also rose significantly over the same period, underlining the growing importance of Latin American and African markets for India’s pharmaceutical industry.

Overall, India’s pharmaceutical exports grew by around 6.5 per cent during the eight-month period, reaching approximately USD 20.5 billion. The United States continued to be the largest export market, accounting for nearly one-third of total pharmaceutical exports. Other European and African markets, including France, the Netherlands, Canada, Germany and South Africa, also reported steady growth.

Industry experts attribute the rising demand from Brazil and Nigeria to expanding healthcare access, increased government procurement, and a strong preference for cost-effective, high-quality generic medicines supplied by Indian manufacturers. These markets are increasingly relying on Indian pharmaceutical products to meet growing public health needs.

The increasing contribution from emerging economies such as Brazil and Nigeria reflects India’s evolving export strategy, which balances dependence on traditional markets with expansion into high-growth regions. This diversification is expected to strengthen India’s position as a reliable and resilient global supplier of pharmaceutical products.